Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $549.96M | $458.12M | $2.65 |
| 2024 | $630.20M | $37.73M | $0.22 |
| 2023 | $838.00M | $100.78M | $0.60 |
| 2022 | $426.41M | $-360.83M | $-2.15 |
| 2021 | $356.13M | $-194.65M | $-1.25 |
Social Signal Score
Earnings
Thu, Mar 4(in 7 months)
Consensus estimate $0.21 per share
Typical surprise +78.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.05 vs $0.14miss
- Thu, Jul 2$0.05 vs $-0.36beat
- Thu, Mar 5$0.00 vs $2.50miss
- Thu, Aug 7$2.60 vs $1.46beat
- Wed, Jul 2$1.35 vs $-0.32beat
- Wed, Mar 19$0.07 vs $0.04beat
Estimates and results for HCM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HCM officers and directors.
No open-market trades in the recent filings. All 52 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.92
- Implied price
- $19.61
- Return from $12.20
- 10.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $9.75 — -20.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 1 | 3 | 5 | 7 | 9 |
|---|---|---|---|---|---|
| -2.0% | -27.7% | -9.9% | -0.2% | 6.7% | 12.2% |
| 3.0% | -24.0% | -5.3% | 4.9% | 12.2% | 17.9% |
| 8.0% | -20.3% | -0.7% | 10.0% | 17.6% | 23.7% |
| 13.0% | -16.6% | 3.9% | 15.0% | 23.1% | 29.4% |
| 18.0% | -12.9% | 8.5% | 20.1% | 28.5% | 35.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsglobenewswire.com·5h ago·Positive
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® — First global Phase III trial to show significant progression-free and overall survival benefits in this setting —
View source ↗